艾昆纬：2026土耳其肥胖症市场格局白皮书：行业生态、市场动态及司美格鲁肽专利到期影响（英文版）（37页）.pdf

1、White PaperThe Obesity Landscape in Trkiye Ecosystem,market dynamics and the impact of semaglutide LoESİNEM ERTEN,Associate DirectorZLEYHA CEBECİ HİYILMAZ,Senior ConsultantASLIHAN İKİZOLU,Senior ConsultantTable of contentsExecutive summary 11.Obesity:A serious public health burden 32.Obesity managem

2、ent ecosystem 62.1.Preventive policies 62.2.Diagnostic framework 72.3.Treatment modalities 72.3.1.Non-pharmacological lifestyle modifications 72.3.2.Digital solutions in obesity management 72.3.3.Pharmacological treatment 92.3.4.Bariatric surgery 102.4.Patient journey 112.4.1.Key specialties in obes

3、ity management 112.4.2.Role of pharmacists 122.4.3.Pharmacological treatment approach 132.4.4.Patient initiated demand for obesity medications 142.4.5.Key challenges in obesity management and patient journey 142.4.6.Drivers of medication switch 172.4.7.Long-term continuation and maintenance 172.4.8.

4、Upcoming change in the treatment landscape:Oral formulations 183.Obesity market dynamics 203.1.GLP-1 therapies:Market formation 203.1.1.GLP-1 therapies in the Turkish pharmaceutical market 203.1.2.Brand awareness for obesity medications in Trkiye 223.2.Future outlook for obesity market 233.2.1.Globa

5、l obesity market forecast 233.2.2.Trkiye perspective:Growth drivers and barriers for GLP-1 market 234.What to expect after Semaglutides LoE?26Explanations 28References 29About the authors 30Acknowledgements 31Abbreviations 32FIGURESFigure 1:Online services for obesity management in Europe 08Figure 2

6、:Roles by multiple stakeholders in obesity care pathway 12Figure 3:Patients reported negative experiences with obesity medications 15Figure 4:Patients reported top reasons for switch of obesity medication 17Figure 5:Expectations of patients during the maintenance phase 18Figure 6:Monthly sales durin